Q93.51
Angelman syndrome
Clinical Classification Guidelines
Medical Intelligence & Overview
Angelman syndrome is a rare genetic disorder characterized by developmental delays, speech impairments, and unique behavioral traits. Named after the scientist who first described it, this syndrome affects the nervous system, leading to significant challenges in communication and motor skills. Typically diagnosed during childhood, individuals with Angelman syndrome often have a happy demeanor with frequent smiling and laughter, but face ongoing developmental obstacles. Early recognition and management can help improve quality of life, though there is no cure for the condition.
Causes & Symptoms
Clinical Causes: Deletions of a segment of the maternal chromosome 15 (15q11-q13 region) Mutations within the UBE3A gene on the maternal chromosome Paternal uniparental disomy, where both copies of chromosome 15 are inherited from the father Imprinting defects affecting gene expression
Key Symptoms: Severe developmental delays and intellectual disability Frequent laughter, smiling, and Happy demeanor Speech impairments or absence of speech Delay in motor milestones, such as crawling and walking Epileptic seizures that often begin in early childhood Feeding difficulties and failure to thrive in infancy Ataxia, or problems with balance and coordination Jerky, stiff movements and gait abnormalities Distinctive facial features, including a broad, flattened face, deep-set eyes, and a prominent chin Hypopigmentation of the skin and light-colored eyes
Diagnostic & Treatment
Diagnosis Path: Diagnosis of Angelman syndrome involves a combination of clinical assessment and genetic testing. Healthcare providers consider characteristic features such as developmental delays, unique behavioral traits, and physical characteristics. Confirmatory tests include methylation analysis, fluorescence in situ hybridization (FISH), and microarray analysis to identify deletions or mutations in the 15q11-q13 region. Early detection is crucial for appropriate intervention and support planning.
Treatment Protocols: Antiepileptic medications to control seizures Communication therapies, such as speech and augmentative communication devices Physical and occupational therapy to enhance motor skills and coordination Behavioral therapy to manage hyperactivity and maladaptive behaviors Special educational interventions tailored to individual abilities Nutritional support to address feeding issues
Clinical Advice & FAQs
Billing Guidance
Is Q93.51 a billable ICD-10 code?
Yes, Q93.51 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report Q93.51?
Clinical documentation must specify the nature of Angelman syndrome and any associated comorbidities for accurate reporting.
Cite this Clinical Reference